NCT05056662|Unknown
Post-Revascularization Optimization and PHysiological Evaluation of intermediaTe Lesions
PROPHET-FFR
Loading search results
PROPHET-FFR
Sponsor study identifier
observational
1,000
1 country
1
Study Start
June 4, 2020
Actual (reported)Primary Completion
June 4, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
PROPHET-FFR is a single center ambispective registry aiming to explore the impact of post-revascularization functional assessment on later outcomes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 4, 2020
Actual (reported)July 22, 2021
Actual (reported)September 24, 2021
Actual (reported)June 4, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Rate of composite of Major Adverse Cardiovascular Events (MACE) [ Cardiac Death/Myocardial Infarction/Target Vessel Failure (TVF)]
2 years
Rate of any component of MACE (Cardiac Death/Myocardial Infarction/Target Vessel Failure (TVF)]
1 year, 3 years, 5 years
Rate of all-cause Death
1 year, 3 years, 5 years
Rate of recurrent or persistent angina
Patients with negative invasive functional evaluation
Patients with positive invasive functional evaluation undergoing PCI
Patients with positive invasive functional evaluation undergoing PCI and subsequent retest of functional indexes
Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients requiring invasive functional evaluation of epicardial stenosis to guide revascularization.
Policlinico Universitario Agostino Gemelli
Rome, RM, Italy
Galante D, Migliaro S, Di Giusto F, Anastasia G, Petrolati E, Vicere A, Zimbardo G, Cialdella P, Romagnoli E, Aurigemma C, Burzotta F, Trani C, Martin-Reyes R, Baptista SB, Faria D, Amabile N, Raposo L, Crea F, Leone AM. Age and Vasodilator Response to Different Hyperemic Agents: Adenosine versus Contrast Medium. Rev Cardiovasc Med. 2024 Jul 2;25(7):239. doi: 10.31083/j.rcm2507239. eCollection 2024 Jul.
First Submitted
July 22, 2021
First Posted
September 24, 2021
Study Start
June 4, 2020
Actual (reported)Primary Completion
June 4, 2025
Prediction of Adverse Events From Non-PCI Coronary Plaques Using Machine Learning
1 year, 3 years, 5 years
Percentage of change in angina intensity assessed by shortened Seattle Angina Questionnaire-7
1 year, 3 years, 5 years
Rate of cardiac hospitalizations
1 year, 3 years, 5 years
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 30, 2023
Record last verified: 2023-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: